Back

P123
DPP-4 inhibition by Linagliptin prevents cardiac inflammation, fibrosis, hypertrophy, and stiffness in obese ZSF1 rats

Cardiovascular Research

23 April 2018
Organised by: Logo
Read full article
ESC Journals

Contributors

I Cuijpers
I Cuijpers

Author

P Carai
P Carai

Author

A Papageorgiou
A Papageorgiou

Author

T Klein
T Klein

Author

E Jones
E Jones

Author

N Hamdani
N Hamdani

Author

S Heymans
S Heymans

Author

You may be interested in
thumbnail
Congress Presentation
Benefit of treatment with Cemtirestat on connexin 43 in the heart and brown adipose tissue of male Zucker diabetic fatty rats.
11 May 2024
thumbnail
Congress Presentation
Meta-analysis of cardiovascular outcome trials assessing the cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus
27 August 2021
thumbnail
Congress Presentation
The senolyitc drug ABT-263 reverses HFpEF-associated inflammation, endothelial inflammation and fibrosis
30 June 2021
thumbnail
Webinar
GLP-1 RAs and HFpEF: which HFpEF patients should now be receiving GLP-1 RAs?
15 December 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources